Literature DB >> 30006379

CDK12 Changes Telling in Prostate Cancer.

.   

Abstract

A recent study established that patients with metastatic castration-resistant prostate cancer who had mutations that inactivated both CDK12 alleles also exhibited other genetic changes. Results of a small, related study suggest these genetic changes may make tumors more responsive to PD-1 inhibitors. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30006379     DOI： 10.1158/2159-8290.CD-NB2018-093

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

Review 1.  Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer.

Authors:  Vipul Bhatia; Bushra Ateeq
Journal:  Trends Mol Med       Date:  2019-07-25       Impact factor: 11.951

2.  CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/β-catenin pathway.

Authors:  Ning Bai; Fada Xia; Wenlong Wang; Yao Lei; Jiang Bo; Xinying Li
Journal:  J Cancer       Date:  2020-04-27       Impact factor: 4.207

3.  A Novel Prognostic Index Based on Alternative Splicing in Papillary Renal Cell Carcinoma.

Authors:  Zhipeng Wu; Jinhui Liu; Rui Sun; Dongming Chen; Kai Wang; Changchun Cao; Xianlin Xu
Journal:  Front Genet       Date:  2020-01-29       Impact factor: 4.599
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.